

Conference Program

Thursday, March 5

- 6:30 p.m.-8:30 p.m. **Welcome and Opening Keynote Session: Antiangiogenesis at Crossroads**
Plaza International Ballroom G
Session Co-Chairpersons: Helen Chen, Cancer Therapy Evaluation Program (CTEP), National Cancer Institute, Bethesda, MD, and Rakesh K. Jain, Massachusetts General Hospital, Boston, MA
- 6:30 **Heterogeneity of the tumor vasculature: Why doesn't anti-VEGF/VEGF receptor therapy work better?**
Harold F. Dvorak, Beth Israel Deaconess Medical Center, Boston, MA
- 7:10 Title to be announced
Napoleone Ferrara, UC San Diego Moores Cancer Center, La Jolla, CA
- 7:50 **Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia**
Rakesh K. Jain
- 8:30 p.m.-10:00 p.m. **Opening Reception**
Garden Terrace

Friday, March 6

- 7:30 a.m.-8:30 a.m. **Continental Breakfast**
Plaza International Ballroom D/E/F
- 8:30 a.m.-10:00 a.m. **Plenary Session 1: What is Limiting the Clinical Success of Antiangiogenic Therapy?**
Plaza International Ballroom G
- 8:30 **Determination of the magnitude of clinical benefit of angiogenesis inhibitors and molecular imaging to visualize drug behavior**
E. G. Elisabeth De Vries, University Medical Center Groningen, Groningen, The Netherlands
- 9:00 Title to be announced
Tracy T. Batchelor, Harvard Medical School, Massachusetts General Hospital, Boston, MA
- 9:30 **Successes and challenges in antiangiogenesis therapy in gastrointestinal cancer**
Eric Van Cutsem, University of Leuven, Leuven, Belgium
- 10:00 a.m.-10:30 a.m. **Break**
Plaza International Ballroom Foyer

10:30 a.m.-12:00 p.m. **Plenary Session 2: Biomarkers / Novel Imaging to Assess Response – Part 1**
Plaza International Ballroom G

10:30 Title to be announced
Carlos Bais, Genentech, Inc., South San Francisco, CA

11:00 **Biomarkers of response and resistance to antiangiogenic therapy**
Dan G. Duda, Harvard Medical School, Boston, MA

11:30 **Genetic and epigenetic changes underlying resistance to antiangiogenic therapies**
Diether Lambrechts, Vesalius Research Center, Leuven, Belgium

12:00 p.m.-3:00 p.m. **Poster Session A / Lunch (provided)**
Plaza International Ballroom D/E/F

3:00 p.m.-4:30 p.m. **Plenary Session 3: Biomarkers / Novel Imaging to Assess Response – Part 2**
Plaza International Ballroom G

3:00 **Angiopoietin/Tie2 as predictive biomarkers for bevacizumab in ovarian cancer**
Gordon C. Jayson, Christie NHS Foundation Trust, Manchester, United Kingdom

3:30 **Perfusion MRI: A potential biomarker of tumor response in clinical trials**
Kyrre E. Emblem, Oslo University Hospital, Oslo, Norway

4:00 Title to be announced
William C. Aird, Beth Israel Deaconess Medical Center, Boston, MA

4:30 p.m.- **Dinner on Own / Evening Off**

Saturday, March 7

7:30 a.m.-8:30 a.m. **Continental Breakfast**
Plaza International Ballroom D/E/F

8:30 a.m.-10:00 a.m. **Plenary Session 4: Where Do We Go Beyond VEGF? – Part 1**
Plaza International Ballroom G

8:30 Title to be announced
Gabriele Bergers, University of California, San Francisco, CA

9:00 **Complex stromal interactions in pancreatic cancer**
Ben Z. Stanger, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

9:30 **Overcoming obesity-induced resistance to anti-VEGF therapy**
Dai Fukumura, Massachusetts General Hospital/Harvard Medical School, Boston, MA

- 10:00 a.m.-10:30 a.m. **Break**
Plaza International Ballroom Foyer
- 10:30 a.m.-12:30 p.m. **Plenary Session 5: Where Do We Go Beyond VEGF? – Part 2**
Plaza International Ballroom G
- 10:30 **Combinatorial targeting of angiogenic growth factor pathways**
Kari K. Alitalo, University of Helsinki, Helsinki, Finland
- 11:00 **Influence on vessel shape of macrophage metabolism in the tumor hypoxic niche**
Massimiliano Mazzone, Catholic University of Leuven, Leuven, Belgium
- 11:30 Title to be announced
Herbert I. Hurwitz, Duke University Medical Center, Durham, NC
- 12:00 **CLIC3 is secreted by CAFs and enhances angiogenesis and tumor cell invasion by cooperating with TGM2***
Sara Zanivan, Beatson Institute for Cancer Research, Glasgow, United Kingdom
- 12:15 **Obesity promotes resistance to anti-VEGF therapy in breast cancer via pro-inflammatory and angiogenic pathways***
Joao Incio, Harvard Medical School, Boston, MA
- 12:30 p.m.-2:30 p.m. **Free Time / Lunch on Own**
- 2:30 p.m.-4:00 p.m. **Plenary Session 6: Combining Antiangiogenesis and Immunotherapies**
Plaza International Ballroom G
- 2:30 **Immune checkpoint blockade in cancer therapy: New insights and opportunities**
James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, TX
- 3:00 **Antiangiogenesis plus immune checkpoint blockade for the treatment of cancer**
F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA
- 3:30 **CXCR4 inhibition reverts immunosuppressive tumor microenvironment and facilitates anti-PD-1 immunotherapy in sorafenib-treated hepatocellular carcinoma***
Rakesh Ramjiawan, Massachusetts General Hospital, Charlestown, MA
- 3:45 **Intravital imaging of cytolytic activity reveals how poor tumor vascularization and hypoxia limit tumor rejection***
Guy Shakhar, Weizmann Institute of Science, Rehovot, Israel
- 4:00 p.m.-6:30 p.m. **Poster Session B / Reception**
Plaza International Ballroom D/E/F
- 6:30 p.m.- **Dinner on Own/Evening Off**

*Short talks from proffered papers.

Sunday, March 8

- 7:30 a.m.-8:30 a.m. **Continental Breakfast**
Plaza International Ballroom Foyer
- 8:30 a.m.-10:00 a.m. **Plenary Session 7: Why is Antiangiogenesis Not Efficacious in Early Disease Setting?**
Plaza International Ballroom G
- 8:30 **Vascular phenotyping: Using genomics to inform antiangiogenesis****
Laura E. Benjamin, ImClone Systems, New York, NY
- 9:00 **Preclinical modeling of adjuvant and metastatic antiangiogenic therapy: Relevance for better predicting clinical outcomes**
Robert S. Kerbel, Sunnybrook Research Institute, Toronto, ON, Canada
- 9:30 **An assessment of the prognostic and predictive associations of 13 angiogenic biomarkers in women with newly diagnosed advanced ovarian cancer treated with chemotherapy with or without bevacizumab***
Wei Wei, Massachusetts General Hospital, Boston, MA
- 9:45 **Formation of lymph node metastases is not angiogenesis dependent***
Timothy P. Padera, Massachusetts General Hospital, Boston, MA
- 10:00 a.m.-10:15 a.m. **Break**
Plaza International Ballroom Foyer
- 10:15 a.m.-11:45 a.m. **Closing Keynote Session: Antiangiogenesis: Safety Issues and Endothelial Metabolism**
Plaza International Ballroom G
Session Chairpersons: Peter Carmeliet, Vesalius Research Center, Leuven, Belgium, and Helen Chen, Cancer Therapy Evaluation Program (CTEP), National Cancer Institute, Bethesda, MD
- 10:15 **Angiogenesis revisited: Principles and strategies**
Peter Carmeliet
- 11:00 **Tolerability of antiangiogenic therapies and novel combinations: Search for the optimal therapeutic window**
Helen Chen
- 11:45 a.m. **Departure**

*Short talks from proffered papers.

**Not designated for CME credit.